尔康制药2025年净利预亏3.25亿元至3.85亿元

Core Viewpoint - Erkang Pharmaceutical (300267) is expected to report a net profit loss of between -325 million to -385 million yuan for the year 2025, primarily due to asset impairment losses related to underutilized production capacity and unfavorable market conditions [1] Group 1 - The company anticipates a significant net loss for 2025, projecting a range of -325 million to -385 million yuan [1] - The expected loss is attributed to a cautious approach regarding current underutilization of production capacity [1] - The company has conducted impairment tests on certain assets and inventories, leading to the recognition of corresponding asset impairment losses [1]